The pandemic won’t last forever, but the virus that causes COVID-19 might. Here we look at what we can expect over the next couple of years in a Q&A with Dr Lee Hampton, pediatrician and medical epidemiologist at Gavi.

The tracking of antibodies in Ebola survivors suggests they wax and wane, which could make vaccine booster shots necessary.

Saving the planet from catastrophic climate change will require not only a dramatic increase in funding for clean-energy research and development. We need innovation in policy just as much as in technology.

New programme makes compensation available to eligible individuals in 92 low- and middle-income countries without need to resort to law courts.

The world's most advanced economies will incur half the total costs associated with a failure to vaccinate poorer nations, which could exceed $4 trillion if only half their citizens are inoculated.

With three major coronavirus outbreaks in the last two decades – first SARS-CoV, then MERS-CoV, and now SARS-CoV-2 that causes COVID-19 – another outbreak is inevitable. Scientists are calling for the world to step up the search for a universal…

A new trial about to start in the UK will deliberately infect people with the virus that causes COVID-19 – if we have vaccines already, why do we need this?

Today G7 leaders announced a doubling of funding for Gavi COVAX AMC to support lower-income economies obtain life-saving vaccines against COVID-19, ensuring greater equity in fighting to end the acute phase of the pandemic.

If we are to minimize the impact of future disease outbreaks, we must recognize the importance of immunization and invest in preemptive vaccine development, writes Tim Keys.

As wearing face masks in public becomes the new normal across the world, what can we learn from a country like Japan, where this has been a long-established practice?

The global effort to contain COVID-19 risks disrupting campaigns against other diseases. Will the fight to control the deadly rabies virus in India be among them?

The World Health Organization has given the Oxford-AstraZeneca vaccine an Emergency Use Listing, passing an important milestone before the first delivery of COVAX vaccines worldwide.